IGMS Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

Open

VWAP

Vol

Mkt Cap

390.15M

Low

Amount

EV/EBITDA(TTM)

-1.59

Total Shares

-27.73M

EV/OCF(TTM)

P/S(TTM)

0.54

IGM Biosciences, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing and delivering a new class of medicines to treat patients with cancer and autoimmune and inflammatory diseases. The Company’s pipeline of clinical and preclinical assets is based on the IgM antibody, which has 10 binding sites compared to conventional IgG antibodies with only two binding sites. It is also focused on creating, developing, manufacturing, and commercializing IgM antibody agonists against oncology and immunology and inflammation targets. The Company’s development programs include Aplitabart, Imvotamab, and IGM-2644. Aplitabart is an IgM antibody targeting Death Receptor 5 (DR5) proteins, being evaluated in multiple phase I combination trials for the treatment of colorectal cancer. Imvotamab is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins. IGM-2644 is a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins.

Events Timeline

(ET)

2025-07-01

09:04:30

IGM Biosciences be acquired by Concentra for $1.247 in cash per share

News

3.5

2025-12-17Businesswire

iGMS Launches AI Features Reducing Guest Communication Time to 1.5 Hours

9.5

2025-08-01NASDAQ.COM

IGM Biosciences, Inc. (IGMS) Q2 Earnings and Revenues Surpass Estimates

7.0

2025-07-05Globenewswire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OLO, SPTN, IGMS on Behalf of Shareholders

8.5

2025-07-02Globenewswire

$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of IGM Biosciences, Inc. (NASDAQ: IGMS)

7.0

2025-07-01PRnewswire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GNTY, IGMS, SPTN, DNOW on Behalf of Shareholders

4.0

2025-06-12Yahoo Finance

IGM Biosciences price target lowered to $1 from $2 at Truist

2 Analyst Rating

Wall Street analysts forecast IGMS stock price to rise

0 Buy

2 Hold

0 Sell

Hold

Current: 0.000

Low

1.00

Averages

1.00

High

1.00

Current: 0.000

Low

1.00

Averages

1.00

High

1.00

BofA

Underperform -> No Rating

downgrade

$1.247

AI Analysis

2025-07-01

Reason

BofA

Price Target

$1.247

AI Analysis

2025-07-01

downgrade

Underperform -> No Rating

Reason

BofA moves to No Rating from Underperform on IGM Biosciences after the company announced an agreement to be acquired by Concentra Biosciences for $1.247 per share in cash and a variable non-tradable contingent value right. IGM shares are no longer trading on fundamentals following the deal announcement, the analyst says.

Truist

Hold

downgrade

$2 -> $1

2025-06-11

Reason

Truist

Price Target

$2 -> $1

2025-06-11

downgrade

Hold

Reason

Truist lowered the firm's price target on IGM Biosciences to $1 from $2 and keeps a Hold rating on the shares. The firm has updated tis model to reflect Q1 financial results and the company's forward outlook, adding that it is waiting for any potential announcement regarding a strategic pivot from the company, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for IGMS

Unlock Now

Valuation Metrics

The current forward P/E ratio for IGM Biosciences Inc (IGMS.O) is -1.45, compared to its 5-year average forward P/E of -4.42. For a more detailed relative valuation and DCF analysis to assess IGM Biosciences Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.42

Current PE

-1.45

Overvalued PE

-0.72

Undervalued PE

-8.11

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-2.04

Current EV/EBITDA

2.09

Overvalued EV/EBITDA

1.01

Undervalued EV/EBITDA

-5.08

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

82.04

Current PS

11.79

Overvalued PS

200.84

Undervalued PS

-36.75

Financials

AI Analysis

Annual

Quarterly

Whales Holding IGMS

Trading Trends

People Also Watch

Frequently Asked Questions

What is IGM Biosciences Inc (IGMS) stock price today?

The current price of IGMS is 0 USD — it has increased 0

What is IGM Biosciences Inc (IGMS)'s business?

What is the price predicton of IGMS Stock?

Wall Street analysts forecast IGMS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IGMS is1.00 USD with a low forecast of 1.00 USD and a high forecast of 1.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is IGM Biosciences Inc (IGMS)'s revenue for the last quarter?

IGM Biosciences Inc revenue for the last quarter amounts to 143.62M USD, increased 11353.19

What is IGM Biosciences Inc (IGMS)'s earnings per share (EPS) for the last quarter?

IGM Biosciences Inc. EPS for the last quarter amounts to 1.58 USD, decreased -300.00

How many employees does IGM Biosciences Inc (IGMS). have?

IGM Biosciences Inc (IGMS) has 149 emplpoyees as of March 19 2026.

What is IGM Biosciences Inc (IGMS) market cap?

Today IGMS has the market capitalization of 390.15M USD.

IGMS Overview

IGMS Overview

Events Timeline

News

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Whales Holding IGMS

Trading Trends

People Also Watch

Frequently Asked Questions

What is IGM Biosciences Inc (IGMS) stock price today?

What is IGM Biosciences Inc (IGMS)'s business?

What is the price predicton of IGMS Stock?

What is IGM Biosciences Inc (IGMS)'s revenue for the last quarter?

What is IGM Biosciences Inc (IGMS)'s earnings per share (EPS) for the last quarter?

How many employees does IGM Biosciences Inc (IGMS). have?

What is IGM Biosciences Inc (IGMS) market cap?